The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors.
 
Misako Nagasaka
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Genentech; Janssen; Lilly; Mirati Therapeutics; Novartis; Pfizer; Takeda
Speakers' Bureau - Blueprint Medicines; Takeda
Research Funding - Tempus
Travel, Accommodations, Expenses - Anheart Therapeutics
 
Shunichi Sugawara
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL; Yakult Honsha
 
Chang-Min Choi
Employment - Procuratio
Stock and Other Ownership Interests - Procuratio
 
Tatsuro Okamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Johnson & Johnson; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Towa Pharmaceutical
Research Funding - AnHeart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); KM Biologics (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Noriko Yanagitani
Consulting or Advisory Role - Chugai Pharma
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical
 
Kaname Nosaki
Honoraria - AstraZeneca; Chugai Pharma; Janssen; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Takeda (Inst)
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); AstraZeneca Japan (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD K.K. (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Yutaka Fujiwara
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; MSD; Ono Pharmaceutical; Otsuka
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst)
 
Hidetoshi Hayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Pfizer; Shanghai HaiHe Pharmaceutical
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
John Khoury
No Relationships to Disclose
 
Jorge J. Nieva
Stock and Other Ownership Interests - Cansera; Epic Sciences; Indee P/L; Quantgene
Consulting or Advisory Role - AstraZeneca; Naveris
Research Funding - Genentech (Inst); Merck (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending - movement and unexpected healthcare encounters
 
A. Eli Gabayan
No Relationships to Disclose
 
Luis E. Raez
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Heat Biologics (Inst); Loxo (Inst); Merck (Inst); Merck Serono (Inst); NantHealth (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst)
 
Hongbin Chen
No Relationships to Disclose
 
Anastasios Dimou
Honoraria - Intellisphere; Intellisphere (Inst); Intellisphere (Inst); Roche/Genentech
Consulting or Advisory Role - TP Therapeutics (Inst)
Research Funding - Novartis (Inst); Syntrix Biosystems (Inst)
Other Relationship - Rising Tide Foundation (Inst)
 
Nathan A. Pennell
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cota Healthcare; G1 Therapeutics; Genentech; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Sanofi/Regeneron; Viosera Therapeutics; Xencor
Research Funding - Altor BioScience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Heat Biologics (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); WindMIL (Inst)
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Jazz Pharmaceuticals; Merck; novartis; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - Elevation Oncology; Turning Point Therapeutics
Honoraria - ARIAD/Takeda; BeiGene; Caris Life Sciences; Daiichi Sankyo; Dava Oncology; Johnson & Johnson/Janssen; Lilly; Pfizer
Consulting or Advisory Role - BeiGene; Daiichi Sankyo; Elevation Oncology; Janssen; Lilly; Pfizer; Takeda
Speakers' Bureau - Caris Life Sciences
Research Funding - ARIAD (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Takashi Seto
Employment - Precision Medicine Asia
Honoraria - Chugai Pharma; Covidien; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda; Towa Pharmaceutical
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Lilly Japan (Inst); LOXO (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)